Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes
Updated December 7, 2025 – for information only, not investment advice. Novo Nordisk stock today: from market darling to turnaround story Novo Nordisk (NYSE: NVO), the Danish giant behind GLP‑1 blockbusters Wegovy and Ozempic, has gone from Europe’s most valuable listed company to a bruised turnaround story in 2025. For investors, NVO has abruptly shifted from a “can do no wrong” growth icon to a complex mix of structural strengths (dominant GLP‑1 franchise, deep pipeline, global reach) and cyclical headaches (pricing pressure, competition, R&D setbacks). The Alzheimer’s shock: EVOKE and EVOKE+ miss their goal The biggest single blow of 2025